{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:47:01Z","timestamp":1778986021841,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.josat.2023.208980","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T20:49:03Z","timestamp":1676494143000},"page":"208980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019"],"prefix":"10.1016","volume":"147","author":[{"given":"Stephen C.","family":"Ijioma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard D.","family":"Chilcoat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela M.","family":"DeVeaugh-Geiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2S Suppl 1","key":"10.1016\/j.josat.2023.208980_bb0010","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MLR.0000000000001530","article-title":"Quality of buprenorphine care for insured adults with opioid use disorder","volume":"59","author":"Anderson","year":"2021","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2023.208980_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108715","article-title":"Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing","volume":"138","author":"Andraka-Christou","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208980_bb0025","series-title":"Current population reports, P60-260, health insurance coverage in the United States: 2016","author":"Barnett","year":"2017"},{"issue":"12","key":"10.1016\/j.josat.2023.208980_bb0030","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1377\/hlthaff.2019.00859","article-title":"In rural areas, buprenorphine waiver adoption since 2017 driven by nurse practitioners and physician assistants","volume":"38","author":"Barnett","year":"2019","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2023.208980_bb0035","series-title":"Current population reports, P60-264, health insurance coverage in the United States: 2017","author":"Berchick","year":"2018"},{"key":"10.1016\/j.josat.2023.208980_bb0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bja\/57.2.192","article-title":"Clinical actions of fentanyl and buprenorphine","volume":"57","author":"Boas","year":"1985","journal-title":"British Journal of Anaesthia"},{"issue":"1","key":"10.1016\/j.josat.2023.208980_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0091270012436561","article-title":"Opioid shopping behavior: how often, how soon, which drugs, and what payment method","volume":"53","author":"Cepeda","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.josat.2023.208980_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpain.2012.10.012","article-title":"Comparison of opioid doctor shopping for tapentadol and oxycodone: A cohort study","volume":"14","author":"Cepeda","year":"2013","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.josat.2023.208980_bb0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: Motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208980_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.drugalcdep.2016.06.009","article-title":"Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin)","volume":"165","author":"Chilcoat","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208980_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208980_bb0070","author":"Drug Addiction Treatment Act of 2000"},{"issue":"2","key":"10.1016\/j.josat.2023.208980_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"8","key":"10.1016\/j.josat.2023.208980_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Network Open"},{"issue":"9","key":"10.1016\/j.josat.2023.208980_bb0090","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1176\/appi.ps.201900635","article-title":"Increases in providers with buprenorphine waivers in the United States from 2016 to 2019","volume":"71","author":"Ghertner","year":"2020","journal-title":"Psychiatric Services"},{"issue":"10","key":"10.1016\/j.josat.2023.208980_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2023.208980_bb0100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant prescribing of opioids and benzodiazepines, 2002\u20132014","volume":"51","author":"Hwang","year":"2016","journal-title":"American Journal of Preventive Medicine"},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0105","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2023.208980_bb0110","series-title":"U.S. Census Bureau current population reports, P60-271, health insurance coverage in the United States: 2019","author":"Keisler-Starkey","year":"2020"},{"key":"10.1016\/j.josat.2023.208980_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109336","article-title":"The effect of medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States","volume":"232","author":"Knudsen","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.208980_bb0120","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.josat.2023.208980_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among us adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2023.208980_bb0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014\u20132018","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2023.208980_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.208980_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108130","article-title":"Age disparities in six-month treatment retention for opioid use disorder","volume":"213","author":"Mintz","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.josat.2023.208980_bb0145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1176\/appi.ps.202000491","article-title":"Changes in buprenorphine treatment after Medicaid expansion","volume":"72","author":"Olfson","year":"2021","journal-title":"Psychiatric Services"},{"issue":"3","key":"10.1016\/j.josat.2023.208980_bb0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009\u20132018","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/add.14886","article-title":"Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine","volume":"115","author":"Park","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2023.208980_bb0160","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"10.1016\/j.josat.2023.208980_bb0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"4","key":"10.1016\/j.josat.2023.208980_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1588","article-title":"Changes in buprenorphine naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion","volume":"1","author":"Saloner","year":"2018","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.208980_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0180","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment","volume":"108","author":"Sharp","year":"2018","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2023.208980_bb0185","article-title":"Doctor shopping behavior and the diversion of prescription opioids","volume":"11","author":"Simeone","year":"2017","journal-title":"Substance Abuse: Research and Treatment"},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5996","article-title":"Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements","volume":"5","author":"Spetz","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.208980_bb0195","series-title":"Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS publication no. PEP20-07-01-001, NSDUH series H-55)","year":"2020"},{"key":"10.1016\/j.josat.2023.208980_bb0210","series-title":"Keys facts about the uninsured population","author":"Tolbert","year":"2022"},{"key":"10.1016\/j.josat.2023.208980_bb0220","unstructured":"U. S. Food and Drug Administration, n.d. bU. S. Food and Drug Administration. (n.d. b). Approved Risk Evaluation and Mitigation Strategies (REMS), Buprenorphine Transmucosal Products for Opioid Dependence (BTOD) Shared REMS System REMS Materials |Appropriate Use Checklist. Retrieved November 29, 2022, from BTOD_2022_05_03_Appropriate_Use_Checklist.pdf (fda.gov)."},{"issue":"5","key":"10.1016\/j.josat.2023.208980_bb0240","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.josat.2023.208980_bb0245","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Medical Care"},{"issue":"4","key":"10.1016\/j.josat.2023.208980_bb0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5055\/jom.2017.0389","article-title":"Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse","volume":"13","author":"Wollschlaeger","year":"2017","journal-title":"Journal of Opioid Management"},{"issue":"1","key":"10.1016\/j.josat.2023.208980_bb0255","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: An international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Current Drug Abuse Reviews"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:39:13Z","timestamp":1762652353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":43,"alternative-id":["S2949875923000309"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.208980","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.208980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"208980"}}